Yoshioka T, Omae K, Funada S, Minami T, Goto R
BJUI Compass. 2025; 6(1):e471.
PMID: 39877574
PMC: 11771497.
DOI: 10.1002/bco2.471.
Badshah M, Ibrahim J, Su N, Whiley P, Middendorff R, Whittaker M
Biomedicines. 2024; 12(3).
PMID: 38540287
PMC: 10968663.
DOI: 10.3390/biomedicines12030674.
Pasha A, Tondo A, Favre C, Calvani M
Biomolecules. 2024; 14(2).
PMID: 38397396
PMC: 10887351.
DOI: 10.3390/biom14020159.
Yamamoto S, Kusabuka H, Matsuzawa A, Maruyama I, Yamazaki T
PLoS One. 2023; 18(9):e0290685.
PMID: 37656760
PMC: 10473532.
DOI: 10.1371/journal.pone.0290685.
Shin J, Jeong S, Kim S, Oh C, Chung K, Shin D
Int Neurourol J. 2023; 27(2):106-115.
PMID: 37401021
PMC: 10325944.
DOI: 10.5213/inj.2346022.011.
Vibegron 50 mg Once Daily Improves OABSS, OAB-q SF Score in OAB Patients ≥80 Years Old in Real-World Clinical Settings and Switching from Other OAB Drugs May Reduce Residual Urine Volume.
Kuno T, Tamura K, Shimizu N, Fukuhara H, Fukata S, Ashida S
Res Rep Urol. 2023; 15:157-164.
PMID: 37251707
PMC: 10216872.
DOI: 10.2147/RRU.S411841.
Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016-2020): A Recapitulation of Chirality.
Tamatam R, Shin D
Pharmaceuticals (Basel). 2023; 16(3).
PMID: 36986439
PMC: 10052577.
DOI: 10.3390/ph16030339.
Latest Advancements on Combating Obesity by Targeting Human Brown/Beige Adipose Tissues.
Pan R, Chen Y
Front Endocrinol (Lausanne). 2022; 13:884944.
PMID: 35600577
PMC: 9114493.
DOI: 10.3389/fendo.2022.884944.
Clinical Utility of β-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations.
Krhut J, Skugarevska B, Mika D, Lund L, Zvara P
Res Rep Urol. 2022; 14:167-175.
PMID: 35502186
PMC: 9056051.
DOI: 10.2147/RRU.S309144.
Pharmacophore-guided Virtual Screening to Identify New β -adrenergic Receptor Agonists.
Ujiantari N, Ham S, Nagiri C, Shihoya W, Nureki O, Hutchinson D
Mol Inform. 2021; 41(7):e2100223.
PMID: 34963040
PMC: 9400856.
DOI: 10.1002/minf.202100223.
Current pharmacotherapy of overactive bladder.
Kreydin E, Gomes C, Cruz F
Int Braz J Urol. 2021; 47(6):1091-1107.
PMID: 34003613
PMC: 8486454.
DOI: 10.1590/S1677-5538.IBJU.2021.99.12.
Metabolic Improvement via Enhancing Thermogenic Fat-Mediated Non-shivering Thermogenesis: From Rodents to Humans.
Pan R, Zhu X, Maretich P, Chen Y
Front Endocrinol (Lausanne). 2020; 11:633.
PMID: 33013706
PMC: 7511774.
DOI: 10.3389/fendo.2020.00633.
Recent advances in managing overactive bladder.
Araklitis G, Baines G, Da Silva A, Robinson D, Cardozo L
F1000Res. 2020; 9.
PMID: 32968482
PMC: 7489273.
DOI: 10.12688/f1000research.26607.1.
Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient.
Makhani A, Thake M, Gibson W
Clin Interv Aging. 2020; 15:575-581.
PMID: 32368024
PMC: 7185319.
DOI: 10.2147/CIA.S174402.
Combating Obesity With Thermogenic Fat: Current Challenges and Advancements.
Pan R, Zhu X, Maretich P, Chen Y
Front Endocrinol (Lausanne). 2020; 11:185.
PMID: 32351446
PMC: 7174745.
DOI: 10.3389/fendo.2020.00185.
Identification of key candidate genes and molecular pathways in white fat browning: an anti-obesity drug discovery based on computational biology.
Pan Y, Liu J, Qi F
Hum Genomics. 2019; 13(1):55.
PMID: 31699147
PMC: 6836481.
DOI: 10.1186/s40246-019-0239-x.
Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care.
Ali M, Grogan S, Powell S, Staniford L, Nazir J, Landeira M
Adv Ther. 2019; 36(11):3110-3122.
PMID: 31559603
PMC: 6822799.
DOI: 10.1007/s12325-019-01098-y.
Everything You Always Wanted to Know about β-AR * (* But Were Afraid to Ask).
Schena G, Caplan M
Cells. 2019; 8(4).
PMID: 30995798
PMC: 6523418.
DOI: 10.3390/cells8040357.